HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended June 30, 2025 ("the Reporting Period") on August 22, 2025.The Group reported sustained revenue growth and significantly improved expense ratios, driving a structural enhancement in profitability. Revenue reached RMB353.4 million, up 17.3% period-to-period. Revenue ...